At a glance
- Iseganan is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 59 publications mentioning it, including 6 randomized controlled trials and 7 animal-only studies.
- ClinicalTrials.gov lists 2 registered studies testing it (0 active).
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Functional hyaluronic acid/gelatin hydrogel accelerates the closure and healing of diabetic wounds.
- Peptide-based antibiotics: structure-driven strategies to tackle toxicity and resistance of antimicrobial peptides.
- Comparisons of successful and failed Phase III trials of drugs and biologicals tested for mitigation of oral mucositis in patients being treated with radiotherapy with or without concomitant chemotherapy for cancers of the head and neck.
- Oropharyngeal Decontamination for Prevention of VAP in Patients Admitted to Intensive Care Units: A Systematic Review.
- Role of Daptomycin in Cutaneous Wound Healing: A Narrative Review.
- Utilisation of peptides against microbial infections - a review.
- Genomic Signatures of Experimental Adaptation to Antimicrobial Peptides in Staphylococcus aureus.
- Treatment of oral mucositis due to chemotherapy.
- Mouth-rinses for the prevention of chemotherapy induced oral mucositis in children: a systematic review.
- In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 2
- Active
- 0
- With posted results
- 0
Conditions studied
| Study | Status | Phase | Start |
|---|---|---|---|
| Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia | Terminated | Phase 2, Phase 3 | Sep 2003 |
| Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer | Unknown status | Phase 3 | Dec 2000 |
All 2 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.